For research use only. Not for human consumption. · Nationwide shipping · 18+

NVNuVida Vital
Shop
CJC-1295 (no DAC) — lyophilized powder in a sealed glass vial with crimp sealLyophilized powder

CJC-1295 (no DAC)

CJC-1295 without DAC / Modified GRF (1-29)

CJC-1295 without DAC — more precisely Modified GRF (1-29) — is a 29-amino-acid GHRH analog carrying four substitutions (D-Ala2, Gln8, Ala15, Leu27) that increase stability against DPP-4 cleavage and plasma degradation. The 'no DAC' designation distinguishes it from the drug affinity complex variant, which incorporates a maleimido group for albumin conjugation and a substantially longer half-life. The two are frequently conflated in supplier catalogs; they are pharmacokinetically very different molecules.

Research applications

  • GHRH receptor binding and activation studies
  • Comparative half-life studies against DAC-conjugated variants
  • Combination studies with GHS-R1a agonists
  • Enzymatic stability and degradation kinetics

Storage

Store lyophilized powder at -20°C protected from light. Reconstituted solution stable at 2-8°C for up to 30 days.

Reconstitution

Reconstitute with bacteriostatic water directed down the vial wall. Swirl gently until dissolved.

Published literature

253 papers indexed on PubMed for CJC-1295 (no DAC). Showing 6, reviews first.

  1. 01
    A new era of doping? Use of peptide and peptide-analog drugs in recreational and professional sport and bodybuilding: a critical review

    Coutinho LFD et al. · J Sports Med Phys Fitness · 2026

    ReviewPMID 41880199doi:10.23736/S0022-4707.26.17773-1

  2. 02
    PEGylation of growth hormone-releasing hormone (GRF) analogues

    Esposito P et al. · Adv Drug Deliv Rev · 2003

    ReviewPMID 14499707doi:10.1016/s0169-409x(03)00109-1

  3. 03
    When the light turns blue

    Barkan A · Endocrinology · 1997

    ReviewPMID 9348173doi:10.1210/endo.138.11.5646

  4. 04
    Growth hormone releasing hormone

    Grossman A et al. · Clin Endocrinol Metab · 1986

    ReviewPMID 2429796doi:10.1016/s0300-595x(86)80012-3

  5. 05
    Growth hormone - releasing hormone antagonists induce autophagy in cancer cells

    Sigdel M et al. · Growth Horm IGF Res · 2025

    PMID 41075421doi:10.1016/j.ghir.2025.101668

  6. 06
    Growth Hormone-Releasing Hormone Antagonists Increase Radiosensitivity in Non-Small Cell Lung Cancer Cells

    Gesmundo I et al. · Int J Mol Sci · 2025

    PMID 40244089doi:10.3390/ijms26073267

Indexed from PubMed, 2026-07-19. We link to sources rather than reproducing them.

Related compounds

Ipamorelin — lyophilized powder in a sealed glass vial

Ipamorelin

5–10mg · ≥99% pure

Highly selective pentapeptide ghrelin receptor agonist, notable for minimal cross-activation of other pituitary axes.

CAS
170851-70-4
MW
711.85
Purity
≥99%
In stock
From$39
Tesamorelin — lyophilized powder in a sealed glass vial

Tesamorelin

10–15mg · ≥99% pure

Stabilized 44-amino-acid GHRH analog — the longest GHRH sequence in common research use.

CAS
218949-48-5
MW
5135.86
Purity
≥99%
In stock
From$64
IGF-1 LR3 — lyophilized powder in a sealed glass vial

IGF-1 LR3

1mg · ≥98% pure

83-amino-acid IGF-1 analog engineered for markedly reduced binding to IGF binding proteins.

CAS
946870-92-4
MW
9117.6
Purity
≥98%
In stock
From$69